Oral propranolol in the treatment of proliferating infantile haemangiomas: The British Society for Paediatric Dermatology consensus guidelines.

Solman, L. ; Glover, M. ; Beattie, P.E. ; Buckley, H. ; Clark, S. ; Gach, J.E. ; Giardini, A. ; Helbling, I. ; Hewitt, R.J. ; Laguda, B. ; Langan, S.M. ; Martinez, A.E. ; Murphy, R. ; Proudfoot, L. ; Ravenscroft, J. ; Shahidullah, H. ; Shaw, L. ; Syed, S.B. ; Wells, L. ; Flohr, C. ;
Oral propranolol in the treatment of proliferating infantile haemangiomas: The British Society for Paediatric Dermatology consensus guidelines.
Br J Dermatol, 2018;

Infantile haemangiomas (IH) are the most common vascular tumours of infancy. Despite their frequency and potential complications, there are currently no unified UK guidelines for the treatment of IH with propranolol. There are still uncertainties and diverse opinions regarding indications, pre-treatment investigations, its use in PHACES syndrome, and cessation of treatment.

This study used a modified Delphi technique, which involved an international treatment survey, a systematic evidence review of the literature, a face-to-face multidisciplinary panel meeting and anonymous voting.

The expert panel achieved consensus on 47 statements in 8 categories including indications and contraindications for starting propranolol, pre-treatment investigations, starting and target dose, monitoring of adverse effects, the use of propranolol in PHACES syndrome and how to stop treatment.

This consensus guideline will help to standardise and simplify the treatment of IH with oral propranolol across the UK and assist in clinical decision-making. This article is protected by copyright. All rights reserved.